Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Percheron Therapeutics ( (AU:PER) ) has shared an announcement.
Percheron Therapeutics has alerted its shareholders about unauthorized correspondence from Powerhouse Ventures Limited, which included a pre-filled proxy form for an upcoming General Meeting. The company emphasized that these proxy forms, if not submitted directly to the company’s share registry, may be invalid, and urged shareholders to follow proper procedures to ensure their votes are counted.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for rare diseases. Its lead program, avicursen (ATL1102), targets the CD49d receptor and has been investigated for inflammatory conditions like multiple sclerosis and Duchenne muscular dystrophy.
Technical Sentiment Signal: Sell
Current Market Cap: $8.34M
For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue